A2 Milk Lifts China Bet as Supply Constraints Ease

Summary

A2 Milk Company expects revenue of NZ$1.97 billion in FY2026, up 12 percent year-on-year,

and an EBITDA margin of 14.0-14.5 percent. Supply tightness for its China-label infant formula has largely been resolved, with channel inventories returning to target levels. The company acquired Yashily's Pokeno plant for NZ$282 million and received Chinese approval for two new China-label formula registrations,

which are set to launch in Q4 2026.

Commentary

A2 Milk's recent supply volatility and rapid recovery underscore the need for vertical integration in its supply chain. By acquiring the Yashily Pokeno plant, A2 is shifting from contract manufacturing to self-owned capacity, a rare move among New Zealand's mid-sized dairy companies. For local small and medium enterprises, this may reduce subcontracting opportunities in packaging, logistics and ancillary services, but also create niche openings in equipment maintenance and farm management outsourcing.

As China's new national formula registration standards tighten, A2's two new formula approvals strengthen its leading position in New Zealand's infant formula exports to China. Smaller players without self-owned capacity and registration qualifications may need to pivot to adult nutrition or cross-border channels. Once the new capacity comes online in Q4, A2's inventory stability will improve, offering regional distributors a potential restocking window.

However, amid overall market competition, profit margins warrant cautious assessment.

Keywords: a2 Milk Company, revenue growth, infant formula, Pokeno plant, China-label formula, supply chain, inventory improvement, acquisition, EBITDA, China market

Source: Sina